Publikationen

2020:

Andreo P, Burns DT, Kapsch RP, McEwen M, Vatnitsky S, Andersen CE, Ballester F, Borbinha J, Delaunay F, Francescon P, Hanlon MD, Mirzakhanian L, Muir B, Ojala J, Oliver CP, Pimpinella M, Pinto M, de Prez LA, Seuntjens J, Sommier L, Teles P, Tikkanen J, Vijande J, Zink K. Determination of consensus k _Q values for megavoltage photon beams for the update of IAEA TRS-398. Phys Med Biol. 2020 May 7;65(9):095011. doi: 10.1088/1361-6560/ab807b. PMID: 32182598.

Baumann KS, Kaupa S, Bach C, Engenhart-Cabillic R, Zink K. Monte Carlo calculation of beam quality correction factors in proton beams using TOPAS/GEANT4. Phys Med Biol. 2020 Mar 6;65(5):055015. doi: 10.1088/1361-6560/ab6e53. PMID: 31962306.

Baumann KS, Flatten V, Weber U, Lautenschläger S, Eberle F, Zink K, Engenhart-Cabillic R. Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients. Radiat Oncol. 2020 Feb 3;15(1):29. doi: 10.1186/s13014-020-1475-x. Erratum for: Radiat Oncol. 2019 Oct 25;14(1):183. PMID: 32014028; PMCID: PMC6996163.

Burg JM, Horst F, Wulff J, Timmermann B, Vorwerk H, Zink K. Optical range determination of clinical proton beams in water. A comparison with standard measurement methods. Phys Med. 2020 May;73:197-203. doi: 10.1016/j.ejmp.2020.03.012. Epub 2020 May 4. PMID: 32380438.

Eberle F, Lautenschläger S, Engenhart-Cabillic R, Jensen AD, Carl B, Stein M, Debus J, Hauswald H. Carbon Ion Beam Reirradiation in Recurrent High-Grade Glioma. Cancer Manag Res. 2020 Jan 28;12:633-639. doi: 10.2147/CMAR.S217824. PMID: 32095084; PMCID: PMC6995286.

Flatten V, Friedrich A, Engenhart-Cabillic R, Zink K. A phantom based evaluation of the dose prediction and effects in treatment plans, when calculating on a direct density CT reconstruction. J Appl Clin Med Phys. 2020 Mar;21(3):52-61. doi: 10.1002/acm2.12824. PMID: 32176455; PMCID: PMC7075385.

Degenhardt S, Dreffke K, Schötz U, Petersen C, Engenhart-Cabillic R, Rothkamm K, Dahm-Daphi J, Dikomey E, Mansour WY. Establishment of a Transformation Coupled in vitro End Joining Assay to Estimate Radiosensitivity in Tumor Cells. Front Oncol. 2020 Aug 20;10:1480. doi: 10.3389/fonc.2020.01480. PMID: 32974177; PMCID: PMC7468517.

Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, Gauer T, Grosu AL, Schmitt D, Tanadini-Lang S, Moustakis C. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol. 2020 May;196(5):417-420. doi: 10.1007/s00066-020-01603-1. PMID: 32211940; PMCID: PMC7182610.

Hartmann GH, Hensley F, Kapsch RP, Poppe B, Sauer O, Würfel J, Zink K. Ermittlung der Wasser-Energiedosis nach der Sondenmethode gemäß DIN 6800 Teil 1: Vorschlag für eine Erweiterung der Grundgleichung [Detector Based Determination of Water Absorbed Dose According to DIN 6800 Teil 1: Suggestion for an Extension of the Fundamental Formalism]. Z Med Phys. 2020 Feb;30(1):24-39. German. doi: 10.1016/j.zemedi.2019.05.001. Epub 2019 Oct 2. PMID: 31585786.

Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Dieckmann K, Eich HT, Flentje M, Grills I, Eble M, Hope A, Grosu AL, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Guckenberger M. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2020 Jan;142:210-216. doi: 10.1016/j.radonc.2019.07.008. Epub 2019 Aug 17. PMID: 31431371.

Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Blanck O, Dieckmann K, Eich HT, Mantel F, Eble M, Hope A, Grosu AL, Nevinny-Stickel M, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Grills I, Guckenberger M. Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):579-586. doi: 10.1016/j.ijrobp.2020.03.005. Epub 2020 Mar 15. PMID: 32188579.

Lerch S, Berthold S, Ziemann F, Dreffke K, Subtil FSB, Senger Y, Jensen A, Engenhart-Cabillic R, Dikomey E, Wittig A, Eberle F, Schötz U. HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation. Radiother Oncol. 2020 Jul 24;151:134-140. doi: 10.1016/j.radonc.2020.07.032. Epub ahead of print. PMID: 32717362.

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol. 2020 May 1;23:43-49. doi: 10.1016/j.ctro.2020.04.010. PMID: 32420463; PMCID: PMC7218223.

Schötz U, Balzer V, Brandt FW, Ziemann F, Subtil FSB, Rieckmann T, Köcher S, Engenhart-Cabillic R, Dikomey E, Wittig A, Arenz A. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining. Cancers (Basel). 2020 Feb 18;12(2):467. doi: 10.3390/cancers12020467. PMID: 32085396; PMCID: PMC7072694.

Sieron HL, Eberle F, Gress TM, Mahnken AH, Wiegand S. Safety of Prophylactic Gastrostomy Tube Placement and Gastrostomy Tube Usage in Patients Treated by Radio(chemo)therapy for Head and Neck Cancer. Anticancer Res. 2020 Feb;40(2):1167-1173. doi: 10.21873/anticanres.14059. PMID: 32014970.

Simeonov Y, Weber U, Schuy C, Engenhart-Cabillic R, Penchev P, Durante M, Zink K. Monte Carlo simulations and dose measurements of 2D range-modulators for scanned particle therapy. Z Med Phys. 2020 Jul 22:S0939-3889(20)30067-2. doi: 10.1016/j.zemedi.2020.06.008. Epub ahead of print. PMID: 32711939.

Stein M, Dohmen H, Wölk B, Eberle F, Kolodziej M, Acker T, Uhl E, Jensen A. Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields. Front Oncol. 2020 Apr 21;10:477. doi: 10.3389/fonc.2020.00477. PMID: 32373516; PMCID: PMC7186451.

Tikkanen J, Zink K, Pimpinella M, Teles P, Borbinha J, Ojala J, Siiskonen T, Gomà C, Pinto M. Calculated beam quality correction factors for ionization chambers in MV photon beams. Phys Med Biol. 2020 Mar 26;65(7):075003. doi: 10.1088/1361-6560/ab7107. PMID: 31995531.

2019:

Christina Schröder, Rita Engenhart-Cabillic, Sven Kirschner, Eyck Blank, André BuchaliChanges of lung parenchyma density following high dose radiation therapy for thoracic carcinomas – an automated analysis of follow up CT scans Radiat Oncol. 2019; 14: 72.

Steve Seltzsam, Frank Ziemann, Kristin Dreffke, Stefanie Preising, Andrea Arenz, Ulrike Schötz, Rita Engenhart-Cabillic, Ekkehard Dikomey, Andrea Wittig: In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity Transl Oncol. 2019 Mar; 12(3): 417–425.

S. Lautenschlaeger, G. Iancu, V. Flatten, K. Baumann, M. Thiemer, C. Dumke, K. Zink, H. Hauswald, D. Vordermark, C. Mauz-Körholz, R. Engenhart-Cabillic, F. Eberle: Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin’s disease Radiat Oncol. 2019; 14: 157.

Baumann KS, Horst F, Zink K, Gomà C. Comparison of penh, fluka, and Geant4/topas for absorbed dose calculations in air cavities representing ionization chambers in high-energy photon and proton beams. Med Phys. 2019 Oct;46(10):4639-4653.

Hartmann GH, Zink K. A Monte Carlo study on the PTW 60019 microDiamond detector. Med Phys. 2019 Nov;46(11):5159-5172.

Flatten V, Baumann KS, Weber U, Engenhart-Cabillic R, Zink K. Quantification of the dependencies of the Bragg peak degradation due to lung tissue in proton therapy on a CT-based lung tumor phantom. Phys Med Biol. 2019 Aug 1;64(15):155005.

Howitz S, Wiezorek T, Wittig A, Vorwerk H, Zink K. Fluence-weighted average subfield size in helical TomoTherapy. Z Med Phys. 2019 Dec;29(4):337-348.

Fels J, Pigorsch S, Vorwerk H, Engenhart-Cabillic R, van Oorschot B. Palliative care in everyday practice of radiation oncologists : Results from a web-based survey among medical members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2019 Jul;195(7):659-667.

Arenz A, Patze J, Kornmann E, Wilhelm J, Ziemann F, Wagner S, Wittig A, Schoetz U, Engenhart-Cabillic R, Dikomey E, Fritz B. HPV-negative and HPV-positive HNSCC cell lines show similar numerical but different structural chromosomal aberrations. Head Neck. 2019 Nov;41(11):3869-3879.

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective. Front Oncol. 2019 May 10;9:318.

Jensen AD, Debus J. Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck. Radiat Oncol. 2019 Nov 6;14(1):194.

Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol. 2019 May

2018:

Ringbæk TP, Weber U, Santiago A, Iancu G, Wittig A, Grzanka L, Bassler N, Engenhart-Cabillic R, Zink K. Validation of new 2D ripple filters in proton treatments of spherical geometries and non-small cell lung carcinoma cases. Phys Med Biol. 63(24):2450201088/1361-6560

Fels J, Pigorsch S, Vorwerk H, Engenhart-Cabillic R, van Oorschot: Palliative care in everyday practice of radiation oncologists : Results from a web-based survey among medical members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol.10.1007/s00066-018-1403-2

Gökyildirim MY, Grandel U, Hattar K, Dahlem G, Schuetz E, Leinberger FH, Eberle F, Sibelius U, Grimminger F, Seeger W, Engenhart-Cabillic R, Dikomey E, Subtil FSB. Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. Oncotarget 9(48):28976-2898810.18632

Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H,Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T,Stelljes M, Bornhäuser M. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol 5(4):e161-e169 1016/S2352-3026(18)30022-X

Randolph B Caldwell, Herbert Braselmann, Steffen Heuer,Ulrike Schötz, Horst Zitzelsberger Gain-of-function analysis of cis-acting diversification elements in DT40 cells Immunology & Cell Biology96(9):948-957. doi: 10.1111/imcb.12158.

Linge A, Schötz U, Löck S, Lohaus F, von Neubeck C, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M; DKTK-ROG. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC Radiother Oncol.127(1):27-35. doi: 10.1016/j.radonc.2017.12.007

Krombach J, Hennel R, Brix N, Orth M, Schötz U, Ernst A, Schuster J, Zuchtriegel G, Reichel CA, Bierschenk S, Sperandio M, Vogl T, Unkel S, Belka C, Lauber K. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncolmmunology
8(1):e1523097. doi: 10.1080/2162402X

Hartmann GH, Zink K Decomposition of the dose conversion factor based on fluence spectra of secondary charged particles: Application to lateral dose profiles in photon fields. Med Phys10.1002/mp.13081

Daher T, Tur MK, Brobeil A, Etschmann B, Witte B, Engenhart-Cabillic R, Krombach G, Blau W, Grimminger F, Seeger W, Klussmann JP, Bräuninger A, GattenlöhnerCombined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Head Neck40(6):1109-1119. doi: 10.1002/hed.25041

2017:

Frank Ziemann, Steve Seltzsam, Kristin Dreffke, Stefanie Preising, Andrea Arenz, Florentine S.B. Subtil, Thorsten Rieckmann, Rita Engenhart-Cabillic, Ekkehard Dikomey and Andrea Wittig: Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines Oncotarget 8(62): 105170-105183

Baumann K, Witt M, Weber U, Engenhart-Cabillic R, Zink K An efficient method to predict and include Bragg curve degradation due to lung-equivalent material in Monte Carlo codes by applying a density modulation Phys. Med. Biol. 62: 3997 - 4016

Ringbaek T, Simeonov Y, Witt M, Engenhart-Cabillic R, Kraft G, Zink K, Weber U Modulation power of porous materials and usage as ripple filter in particle therapy Phys. Med. Biol. 62: 2892-2909

Christina Schröder, Rita Engenhart-Cabillic, Hilke Vorwerk, Michael Schmidt, Winfried Huhnt, Eyck Blank, Dietrich Sidow, André Buchali Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy Strahlenther Onkol. 2017 Feb;193(2):125-131.

Christina Schröder, Rita Engenhart-Cabillic, Hilke Vorwerk, Michael Schmidt, Winfried Huhnt, Eyck Blank, Dietrich Sidow, André Buchali Patient's quality of life after high-dose radiation therapy for thoracic carcinomas : Changes over time and influence on clinical outcome. Strahlenther Onkol. 2017 Feb;193(2):132-140.

Horst F, Schuy Ch, Weber U, Brinkmann K-T, Zink K. Measurement of charge- and mass-changing cross sections for 4He + 12C collisions in the energy range 80 - 220 MeV/u for applications in ion beam therapy. Phys. Rev. C 96: 024624-1 - 024624-11

Czarnecki D, Poppe B, Zink K Monte Carlo based investigations on the impact of removing the flattening filter on beam quality specifiers for photon beam dosimetry Med. Phys. 44: 2569-2580

Horst F, Fehrenbacher G, Zink K. On the neutron radiation field and air activation around a medical electron linac. Radiation Protection Dosimetry 174: 147-158

Katja Hattar, Christian P. Reinert, Ulf Sibelius, Mira Y. Gökyildirim, Florentine S. B. Subtil, Jochen Wilhelm, Bastian Eul, Gabriele Dahlem, Friedrich Grimminger, Werner Seeger, Ulrich Grandel Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro Cancer Immunol Immunother 66: 799-809

Simeonov Y, Weber U, Penchev P, Printz Ringbæk T, Schuy Ch, Brons S, Engenhart-Cabillic R, Bliedtner J, Zink K. 3D range-modulator for scanned particle therapy: development, Monte Carlo simulations and experimental evaluation. Phys. Med. Biol. 62: 7075-7096

von Voigts-Rhetz P, Vorwerk H, Zink K. On the Perturbation Correction Factor pcav of the Markus Parallel-Plate Ion Chamber in Clinical Electron Beams. Int. J. Med. Phys. Clin.Eng. Rad. Oncol. 6: 150-161.

Hoch S, Thelen K, Vorwerk H, Netzer C, Wilhelm T, Günzel T, Teymoortash A: Impact of Different Treatment Concepts on Regional Failure in Advanced Oropharyngeal Cancer. Anticancer Res. 2017 Feb;37(2):727-734

Wagner DM, Hüttenrauch P, Anton M, von Voigts-Rhetz P, Zink K, Wolff HA: Feasibility study of entrance and exit dose measurements at the contra lateral breast with alanine/electron spin resonance dosimetry in volumetric modulated radiotherapy of breast cancer. Phys Med Biol. 2017 Jul 7;6e2(13):5462-5472

Kuhnt T, Schreiber A, Pirnasch A, Hautmann MG, Hass P, Sieker FP, Engenhart-Cabillic R, Richter M, Dellas K, Dunst J: Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study. Strahlenther Onkol. 2017 Sep;193(9):733-741

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfarth K, Lukas P: New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group Strahlenther Onkol. 2017 Feb;193(2):100-108

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfart K, Lukas P, Plütschow A, Schmidberger H, Marnitz-Schulze S, Fuchs M, Engert A, Eich HT: Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2017 Feb;193(2):109-115

Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Høyer M, Ricardi U, Sterzing F, Guckenberger M. Radiother Oncol. 2017 May;123(2):182-188. doi: 10.1016/j.radonc.2017.01.003. Epub 2017 Feb 4Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease.

Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M: Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):511-520

Eberle F, Leinberger FH, Saulich MF, Seeger W, Engenhart-Cabillic E, Hänze J, Hattar K, Dikomey E, Subtil FSB In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed. Clinical and Translational Radiation Oncology (ISSN 2405-6308): 2017 Volume 2,Pages 69-75.

2016:

Horst F, Schuy Ch, Weber U, Brinkmann K-T, Zink K: Measurement of charge- and mass-changing cross sections for 4He + 12C collisions in the energy range 80 - 220 MeV/u for applications in ion beam therapy. Phys. Rev. C 96: 024624-1 - 024624-11. IF: 3.820 (2016)

Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M: Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):511-520. IF: 4.495 (2016)

Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Høyer M, Ricardi U, Sterzing F, Guckenberger M: Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017 May;123(2):182-188. IF. 4.817 (2016)

Ziemann F; Seltzsam S, Dreffke K, Preising S, Arenz A, Subtil FSB, Rieckmann T, Engenhart-Cabillic R, Dikomey E, Wittig A: Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines. Oncotarget 8(62): 105170-105183. IF: 5.168 (2016)

Eberle F, Leinberger FH, Saulich MF, Seeger W, Engenhart-Cabillic R, Hänze J, Hattar K, Dikomey E, Subtil FS: In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed. Clin Trans Radiat Oncol. 2017;2:69-75. (2016)

Simeonov Y, Weber U, Penchev P, Ringbæk TP, Schuy C, Brons S, Engenhart-Cabillic R, Bliedtner J, Zink K: 3D range-modulator for scanned particle therapy: development, Monte Carlo simulations and experimental evaluation. Phys Med Biol. 2017 Aug 11;62(17):7075-7096. IF: 2.742 (2016)

Hattar K, Reinert CP, Sibelius U, Gökyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger F, Seeger W, Grandel U: Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunol Immunother. 2017 Jun;66(6):799-809. IF: 4.711 (2016)

Czarnecki D, Poppe B, Zink K: Monte Carlo-based investigations on the impact of removing the flattening filter on beam quality specifiers for photon beam dosimetry. Med Phys. 2017 Jun;44(6):2569-2580. IF: 2.496 (2016)

Kuhnt T, Schreiber A, Pirnasch A, Hautmann MG, Hass P, Sieker FP, Engenhart-Cabillic R, Richter M, Dellas K, Dunst J: Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2017 May 12. doi: 10.1007/s00066-017-1145-6. [Epub ahead of print]. IF: 2.735 (2016)

Horst F, Fehrenbacher G, Zink K: On the neutron radiation field and air activation around a medical electron linac. Radiat Prot Dosimetry. 2017 Apr 25;174(2):147-158. IF: 0.894 (2016)

Baumann KS, Witt M, Weber U, Engenhart-Cabillic R, Zink K: An efficient method to predict and include Bragg curve degradation due to lung-equivalent materials in Monte Carlo codes by applying a density modulation. Phys Med Biol. 2017 Mar 21;62(10):3997-4016. IF: 2.742 (2016)

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A: Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo) therapy. Strahlenther Onkol. 2017 Feb;193(2):125-131. doi: 10.1007/s00066-016-1067-8. Epub 2016 Oct 25 IF: 2.735 (2016)

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A: Patient's quality of life after high-dose radiation therapy for thoracic carcinomas : Changes over time and influence on clinical outcome. Strahlenther Onkol. 2017 Feb;193(2):132-140. IF: 2.735 (2016)

Hoch S, Thelen K, Vorwerk H, Netzer C, Wilhelm T, Günzel T, Teymoortash A: Impact of Different Treatment Concepts on Regional Failure in Advanced Oropharyngeal Cancer. Anticancer Res. 2017 Feb;37(2):727-734. IF: 1.895 (2016)

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfarth K, Lukas P, Schmidberger H, Marnitz-Schulze S, Fuchs M, Engert A, Eich HT: New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group. Strahlenther Onkol. 2017 Feb;193(2):100-108. IF: 2.735 (2016)

Toke Printz Ringbæk, Yuri Simeonov, Matthias Witt, Rita Engenhart-Cabillic, Gerhard Kraft, Klemens Zink and Uli Weber Modulation power of porous materials and usage as ripple filter in particle therapy. Phys Med Biol. 2017 Apr7;62(7):2892-2909. IF: 2.742 (2016)

Kriz J, Baues C, Engenhart-Cabillic R, Haverkamp U, Herfart K, Lukas P, Plütschow A, Schmidberger H, Staar S, Fuchs M, Engert A, Eich HT: Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2017 Feb;193(2):109-115. IF: 2.735 (2016)

Eekers DB, Roelofs E, Jelen U, Kirk M, Granzier M, Ammazzalorso F, Ahn PH, Janssens GO, Hoebers FJ, Friedmann T, Solberg T, Walsh S, Troost EG, Kaanders JH, Lambin P: Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016 Dec;121(3):387-394. doi: 10.1016/j.radonc.2016.08.020. Epub 2016 Sep 14. IF: 4.328

von Voigts-Rhetz P, Anton M, Vorwerk H, Zink K: Perturbation correction for alanine dosimeters in different phantom materials in high-energy photon beams Phys Med Biol. 2016 Feb 7;61(3):N70-9. doi: 10.1088/0031-9155/61/3/N70. Epub 2016 Jan 13. IF: 3.41

Schröder C, Engenhart-Cabillic R, Vorwerk H, Schmidt M, Huhnt W, Blank E, Sidow D, Buchali A: A lot to a little or a little to a lot-which dose-volume relationship ensures the best clinical outcome in the high dose radiation therapy of thoracic tumors? A prospective approach. J Thorac Dis. 2016 Aug;8(8):2053-60. doi: 10.21037/jtd.2016.07.92. IF: 2.365

Eberle F, Saulich MF, Leinberger FH, Seeger W, Engenhart-Cabillic R, Dikomey E, Hänze J, Hattar K, Subtil FS: Cancer cell motility is affected through 3D cell culturing and SCF/c-Kit pathway but not by X-irradiation. Radiother Oncol. 2016 Jun;119(3):537-43. IF: 4.817

Ringbæk TP, Weber U, Santiago A, Simeonov Y, Fritz P, Krämer M, Wittig A, Bassler N, Engenhart-Cabillic R, Zink K: Dosimetric comparisons of carbon ion treatment plans for 1D and 2D ripple filters with variable thicknesses. Phys Med Biol. 2016 Jun 7;61(11):4327-41. doi: 10.1088/0031-9155/61/11/4327. Epub 2016 May 20. IF: 2.811

Santiago A, Barczyk S, Jelen U, Engenhart-Cabillic R, Wittig A: Challenges in radiobiological modeling: Can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data? Radiat Oncol. 2016 May 6;11(1):67. doi: 10.1186/s13014-016-0643-5. IF: 2.568

Teymoortash A, Pfestroff A, Wittig A, Franke N, Hoch S, Harnisch S, Schade-Brittinger C, Hoeffken H, Engenhart-Cabillic R, Brugger M, Strauch K: Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial. PLoS One. 2016 Mar 18;11(3):e0151316. doi: 10.1371/journal.pone.0151316. eCollection 2016. IF: 2.806

2015:

Santiago A, Fritz P, Mühlnickel W, Engenhart-Cabillic R, Wittig A: Changes in the radiological depth correlate with dosimetric deterioration in particle therapy for stage I NSCLC patients under high frequency jet ventilation. Acta Oncol. 2015;54(9):1631-7. doi: 10.3109/0284186X.2015.1067716. Epub 2015 Sep 18. IF: 2.997

Horst F, Fehrenbacher G, Radon T, Kozlova E, Rosmej O, Czarnezki D, Schrenk O, Breckow J, Zink K: A TLD-based ten channel system for the spectrometry of bremsstrahlung generated by laser-matter interaction. Nuc. Inst. Meth. Phys. A 782 (2015): 69-76 IF: 1.389

Schmidt R, Wulff J, Zink K: GMctdospp: Description and validation of a CT dose calculation system. Med Phys. 2015 Jul;42(7):4260-70. IF: 2.635

Horst F, Czarnecki D, Zink K: The influence of neutron contamination on dosimetry in external photon beam radiotherapy. Med Phys. 2015 Nov;42(11):6529-36. doi: 10.1118/1.4933246. IF: 2.635

Iancu G, Kraemer M, Zink K, Durante M, Weber U: Implementation of an efficient Monte Carlo algorithm in TRiP: Physical dose calculation. Int J Part Ther 2 (2015):415-425.

Göpfert F, Schmidt R, Wulff J, Zink K: Effect of ROI filtering in 3D cone-beam rotational angiography on organ dose and effective dose in cerebral investigations. J Appl Clin Med Phys. 2015 Mar 8;16(2):5306. doi: 10.1120/jacmp.v16i2.5306. IF: 1.41

Ringbæk TP, Brons S, Naumann J, Ackermann B, Horn J, Latzel H, Scheloske S, Galonska M, Bassler N, Zink K, Weber U. Fluence inhomogeneities due to a ripple filter induced Moiré effect. Phys Med Biol. 2015 Feb 7;60(3):N59-69. doi: 10.1088/0031-9155/60/3/N59. Epub 2015 Jan 15 IF: 3.41

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow, A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K: Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20. IF: 4.258

Kriz J, Reinartz G, Dietlein M, Kobe C, Kuhnert G, Haverkamp H, Haverkamp U, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Staar S, Hegerfeld K, Baues C, Engert A, Eich HT: Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):46-53. doi: 10.1016/j.ijrobp.2015.01.048. IF: 4.258

Ammazzalorso F, Jelen U, Engenhart-Cabillic R, Schlegel W. Dosimetric robustness against setup errors in charged particle radiotherapy of skull base tumors. Radiat Oncol. 2014 Dec 5;9:279. doi: 10.1186/s13014-014-0279-2. IF: 2.360

Witt M, Weber U, Kellner D, Engenhart-Cabillic R, Zink K: Optimization of the stopping-power-ratio to Hounsfield-value calibration curve in proton and heavy ion therapy. Z Med Phys. 2015 Sep;25(3):251-63. IF: 1.811

Ziemann F, Arenz A, Preising S, Wittekindt C, Klussmann JP, Engenhart-Cabillic R, Wittig A: Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation +/- Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am J Cancer Res. 2015 Feb 15;5(3):1017-31. eCollection 2015. IF: 3.968

Olbert PJ, Kesch C, Henrici M, Subtil FS, Honacker A, Hegele A, Hofmann R, Hänze J: TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. Urol Oncol. 2015 Mar;33(3):110.e19-27. IF: 2.768

2014:

Grün R, Friedrich T, Krämer M, Zink K, Durante M, Engenhart-Cabillic R, Scholz M: Assessment of potential advantages of relevant ions for particle therapy: A model based study. Med Phys. 2015 Feb;42(2):1037-47. doi: 10.1118/1.4905374. IF: 2.635

Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M, Grosu AL: Stereotactic radiosurgery for treatment of brain metastases. Strahlenther Onkol. 2014 Jun;190(6):521-32. IF: 2.914

Ammazzalorso F, Jelen U: A 4D dose computation method to investigate motion interplay effects in scanned ion beam prostate therapy. Phys Med Biol. 2014 Jun 7;59(11):N91-9.

Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R: Stereotactic Radiotherapy for Benign Meningioma: Long-Term Outcome in 318 Patients. Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):569-75. IF: 4.176

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy – ten years follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014 Aug6(2):243-50. IF: 12.48

Hattar K, Franz K, Ludwig M, Sibelius U, Wilhelm J, Lohmeyer J, Savai R, Subtil FS, Dahlem G, Eul B, Seeger W, Grimminger F, Grandel U: Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunol Immunother. 2014 Dec;63(12):1297-306.

Kunze K, Frank M, Bodner J, Blau W. Sibelius U, Rummel M, Hörbelt R, Padberg W, Engenhart-Cabillic R, Bräuninger A, Gattenlöhner S: Differentiation of primary and metastatic tumors in synchronous multifocal colonic and bronchopulmonary adenocarcinoma by targeted next generation sequencing. Histopathology. 2014 Jun;64(7):1041-3.

Hüttenrauch P, Witt M, Wolff D, Bosold S, Engenhart-Cabillic R, Sparenberg J, Vorwerk H, Zink K: Target volume coverage and dose to organs at risk in prostate cancer patients: Dose calculation on daily cone-beam CT data sets. Strahlenther Onkol. 2014 Mar;190(3):310-316. IF: 2.914

Chanrion MA, Sauerwein W, Jelen U, Wittig A, Engenhart-Cabillic R, Beuve M: Influence of the Local Effect Model Parameters on the Prediction of Tumor Control Probability for Prostate Cancer. Phys Med Biol. 2014 Jun 21,59(12):3019-40.

Teymoortash A, Pfestroff A, Franke N, Hoch S, Harnisch S, Schade-Brittinger C, Hoeffken H, Merte H, Engenhart-Cabillic R, Brugger M, Strauch K, Wittig A, Werner JA: Safety and efficacy of botulinum toxin to preserve gland function after radiotherapy in patients with head and neck cancer: a prospective, randomized, placebo-controlled, double-blinded phase I clinical trial. PLoS One. 2016 Mar 18;11(3):e0151316. doi: 10.1371/journal.pone.0151316. eCollection 2016.

Ammazzalorso F, Graef S, Weber U, Wittig A, Engenhart-Cabillic R, Jelen U: Dosimetric consequences of intrafraction prostate motion in scanned ion beam radiotherapy. Radiother Oncol. 2014 May 12. pii: S0167-8140(14)00165-0. doi: 10.1016/j.radonc.2014.03.022. IF: 4.857

Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R: Stereotactic Radiotherapy of Benign Meningioma in the Elderly: Clinical outcome and Toxicity in 121 Patients. Radiother Oncol. 2014 May 8. pii: S0167-8140(14)00160-1. IF: 4.857

Vorwerk H, Zink K, Wagner DM, Engenhart-Cabillic R: Making the right software choice fort he clinical used equipment in the radiooncology. Radiat Oncol. 2014 Jun 23;9(1):145. IF: 2.360

Arenz A, Ziemann F, Mayer C, Wittig A, Dreffke K, Preising S, Wagner S Klussmann JP, Engenhart-Cabillic R, Wittekindt C: Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation. Strahlenther Onkol. 2014 Sep;190(9):839-46. IF: 2.914

Zink K, Czarnecki D, Looe HK, von Voigts-Rhetz P, Harder D: Monte Carlo study of the depth-dependence fluence perturbation in parallel-plate chambers electron beams. Med. Phys. 41 (2014) 111707. IF: 2.91

Jelen U, Bubula ME, Ammazzalorso F, Engenhart-Cabillic R, Weber U, Wittig A: Dosimetric impact of reduced nozzle-to-isocenter distance in intensity-modulated proton therapy of intracranial tumors in combined proton-carbon fixed-nozzle treatment facilities. Radiat Oncol. 2013 Sep 18;8(1):218.

Vorwerk H, Zink K, Schiller R, Budach V, Böhmer D, Kampfer S, Popp W, Sack H, Engenhart-Cabillic R. Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT. Strahlenther Onkol. 2014 May;190(5):433-43. doi: 10.1007/s00066-014-0634-0. Epub 2014 Mar 5. IF: 2.914

Dunst J, Willich N, Sack H, Engenhart-Cabillic R, Budach V, Popp W: The QUIRO-Study (assurance of quality and innovation in radiooncology): Methodology, instruments and practices. Strahlenther Onkol. 2014 Feb;190(2):138-148. Epub 2014 Jan 11. IF: 2.914

Subtil FS, Wilhelm J, Bill V, Westholt N, Rudolph S, Fischer J, Scheel S, Seay U, Fournier C, Taucher-Scholz G, Scholz M, Seeger W, Engenhart-Cabillic R, Rose F, Dahm-Daphi J, Hänze J: Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency. FASEB J. 2014 Mar;28(3):1412-21. IF: 5.480

von Voigts-Rhetz P, Czarnecki D, Zink K: Effective point of measurement for parallel plate and cylindrical ion chambers in megavoltage electron beams. Z Med Phys. 2014 Jan 10. pii: S0939-3889(13)00136-0. IF: 2.963

2013:

Steiner E, Stock M, Kostresevic B, Ableitinger A, Jelen U, Prokesch H, Santiago A, Trnková P, Wolf A, Wittig A, Lomax A, Jägel O, Baroni G, Georg D: Imaging dose assessment for IGRT in particle beam therapy. Radiother Oncol. 2013 Dec;109(3):409-13.

Wittig A, Moss R, Sauerwein WAG: Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT. Appl Radiat Isot. 2013 Nov 28. pii: S0969-8043(13)00484-3

Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M: Applicability of the linear-quadratic formalism for modelling local control probability in stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol. 2013 Oct;109(1):13-20. doi: 10.1016/j.radonc.2013.09.005.

Santiago A, Jelen U, Ammazzalorso F, Engenhart-Cabillic R, Fritz P, Mühlnickel W, Enghardt W, Baumann M, Wittig A: Reproducibility of target coverage in stereotactic spot scanning proton lung irradiation high frequency jet ventilation. Radiother Oncol. 2013, 109:45-50.

Fokas E, Henzel M, Wittig A, Grund S, Engenhart-Cabillic R: Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. J Neurol. 2013 Aug; 260(8):2156-62.

Jelen U, Bubula M, Ammazzalorso F, Weber U, Wittig A: Dosimetric impact of reduced nozzle-to-isocenter distance in intensity-modulated proton therapy of intracranial tumors in combined proton-carbon fixed-nozzle treatment facilities. Radiat Oncol. 2013 Sep 18;8(1):218.

Ubrich F, Wulff J, Engenhart-Cabillic R, Zink K: Correction factors for source strength determination in HDR brachytherapy using the in-phantom method. Korrektionsfaktoren zur Bestimmung der Quellenstärke von HDR-Brachytherapie-quellen mittels der Phantom-Methode. Z Med Phys. 2013 Sep 7. doi,pii: S0939-3889(13)00095-0.10.1016/j.zemedi.2013.08.001. [Epub ahead of print].

Guckenberger M, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N: Safety and efficacy of stereotactic body radiotherapy for stage i non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol.2013 Aug;8(8):1050-8.

Grün R, Friedrich T, Krämer M, Zink K, Durante M, Engenhart-Cabillic R, Scholz M: Physical and biological factors determining the effective proton range: An analysis based on the Local Effect Model. Med Phys. 2013 Nov;40(11):111716.

Kueller AM, Schaefer C, Cord S, Engenhart-Cabillic R, Gross MW: Online learning courses for medical undergraduates in the field of radiation oncology - How costly has to be the graphic design? A randomized controlled trial.

Chanrion MA, Ammazzalorso F, Wittig A, Engenhart-Cabillic R, Jelen U: Dosimetric consequences of pencil-beam width vaiations in scanned beam particle therapy. Phys Med Biol. 2013 Jun 21,58(12):3979-93.

Henzel M, Sitter H, Fokas E, Wittig A, Engenhart-Cabillic R: Quality of Life after Stereotactic Radiotherapy for Meningioma: A Prospective Non-radomized Study. J Neurooncol. 2013 May;113(1):135-41.

Brualla L, Sempau J, Zaragoza FJ, Wittig A, Sauerwein W: Accurate estimation of dose distributions inside an eye irradiated with Ru-106 plaques. Strahlenther Onkol. 2013 Jan;189(1):68-73. IF: 2.733

Czarnecki D, Zink K: Monte Carlo calculated correction factors for diodes and ion chambers in smallPhoton fields. Phys Med Biol. 2013 Mar 21;58(8):2431-2444

Hattar K, Savai R, Subtil FSB, Wilhelm J, Schmall A, Lang DS, Goldmann T, Eul B, Dahlem G, Fink L, Schermuly RT, Banat GA, Sibelius U, Grimminger F, Vollmer E, Seeger W, Grandel U: Endotoxin induces proliferation of NSCLC in vitro and in vivo – role of COX-2 and EGFR activation. Cancer Immunol Immunother. 2013 Feb;62(2):309-20 IF: 3.701

2012:

Roelofs E, Engelsman M, Rasch C, Persoon L, Qamhiyeh S, de Ruysscher D,
Verhaegen F, Pijls-Johannesma M, Lambin P; ROCOCO Consortium.
Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer.
J Thorac Oncol. 2012 Jan;7(1):165-76.
IF: 3.661

Bert C, Engenhart-Cabillic R, Durante M:
Particle therapy for noncancer diseases.
Med. Phys. 2012 Apr;39(4): 1716-27
IF: 3.095

Lohr F, Baus W, Vorwerk H, Schlömp B, André L, Georg D, Hodapp N:
Rules and regulations applying to incidents in radiotherapy.
(AG Patientensicherheit der DEGRO/DGMP/VMTRO sowie für die ÖGRO/ÖGMP
and SASRO/SGSMP.
Strahlenther Onkol. 2012 Jul;188(7):545-50.
IF: 3.561

Czarnecki D, Wulff J, Zink K:
The influence of linac spot size on scatter factors.
Metrologia 49 (2012) Aug;S215–S218
IF: 1.750

Jelen U, Ammazzalorso F, Chanrion M-A, Gräf S, Zink K, Engenhart-Cabillic R, Wittig A:
Robustness against interfraction prostate movement in scanned ion beam radiation
therapy.
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e257-62.
IF: 4.503

Grün R, Friedrich T, Elsässer T, Krämer M, Zink K, Karger C, Durante M,
Engenhart-Cabillic R, Scholz M:
Impact of enhancements in the Local Effect Model (LEM) on the predicted RBE
weighted target dose distribution in carbon ion therapy.
Phys Med Biol. 2012 Nov 21;57(22):7261-74.
IF: 2.829

Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R:
Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases
J Neurooncol. 2012 Apr 15 [Epub ahead of print]
IF: 3.214

Combs SE, Kieser M, Habermehl D, Weitz J, Jäger D, Fossati P, Orrechia R,
Engenhart-Cabillic R, Pötter R, Djosanjh M, Jäkel O, Büchler M W, Debus J:
Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent
Rectal Cancer: The PANDORA-01 Trial.
BMC Cancer. 2012 Apr 3;12:137. doi. 10.1186/1471-2407-12-137.
IF: 3.011

Sauerwein W, Engenhart-Cabillic R, Forman JD, Gueulette J, Hachem S, Jones D, Krüll A,
Lukas P, Mandrillon P, Petry W, Rosenberg I, Fert FV, Welsh, JS:
Neutron radiotherapy in South Africa: neutron radiotherapy should continue.
S Afr Med J. 2012 Mar 23;102(5):269-70; author reply 270-1.

Brualla L, Zaragoza FJ, Sempau J, Wittig A, Sauerwein W:
Electron irradiation of conjunctival lymphoma – Monte Carlo simulation of the minute
dose distribution and technique optimization.
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1330-7. Epub 2012 Jan 13.
IF: 4.503

Hattar K, Savai R, Subtil FSB, Wilhelm J, Schmall A, Lang DS, Goldmann T, Eul B,
Dahlem G, Fink L, Schermuly RT, Banat GA, Sibelius U, Grimminger F, Vollmer E,
Seeger W, Grandel U:
Endotoxin induces proliferation of NSCLC in vitro and in vivo – role of COX-2 and EGFR activation.
Cancer Immunol. Immunother. 2012 Aug 26 [Epub ahead of print].
IF: 3.701

Zabel-du Bois A, Milker-Zabel S, Henzel M, Popp W, Debus J, Sack H,
Engenhart-Cabillic R:
Evaluation of time, attendance of medical staff, and resources during stereotactic
radiotherapy/radiosurgery: QUIRO-DEGRO Trial.
Strahlenther Onkol 2012 Aug 188:769-776 DOI 10.1007/s00066-012-0140-1.
IF: 2.541

Zink K, Wulff J:
Beam quality corrections for parallel-plate ion chambers in electron reference
dosimetry.
Phys Med Biol. 57, 1831-1854.
IF: 2.829

Mäder U, Marquardt K, Beer S, Bergmann T, Schmidts T, Heverhagen J, Zink K, Runkel F,
Fiebich M:
Evaluation and quantification of spectral information in tissue by confocal
microscopy.
J Biomed Optics 2012 Oct 17: 106011.
IF: 3.157

Anton M, Kapsch R P, Krauss M, von Voigts-Rhetz P, Zink K, McEwen M
Investigating the difference in the relative response of the alanine dosimeter to megavoltage x-ray and electron beams
submitted to Phys. Med. Biol. (2012)

2011:

Kamlah F, Hänze J, Seay U, Juricko J, Hasan D, Bischoff B, Arenz A, Fournier C,
Taucher-Scholz, G, Scholz M, Seeger W, Engenhart-Cabillic R, Rose F:
Comparison of the effects of carbon ion and photon irradiation on the angiogentic
response in human lung adenocarcinoma cells.
Int J Radiat Oncology Biol Phys 2011 Aug 1;80(5):1541-9. Epub 2011 May 27.
IF: 4.503

Fokas E, An Y, Juricko J, Engenhart-Cabillic R, An H:
Genetic alterations after carbon ion irradiation in human lung adenocarcinoma cells.
Int J Oncol. 2011 Jan;38(1):161-8.
IF: 2.391

Zink K, Wulff J:
On the wall perturbation correction for a parallel-plate NACP-02 chamber in clinical electron beams.
Med Phys. 2011 Feb;38(2):1045-54.
IF: 3.095

Roth J, Engenhart-Cabillic R, Eberhardt L, Timmesfeld N, Strassmann G:
Preoxygenated hyperventilated hypocapnic apnea-induced radiation (PHAIR) in breast
cancer patients.
Radiother Oncol. 2011 Aug;100(2):231-5. Epub 2011 Apr 16.
IF: 4.329

Wittig A, Engenhart-Cabillic R:
Cardiac side-effects of conventional and particle radiotherapy in cancer patients.
Herz. 2011 Jun;36(4):311-324.
IF: 0.712

You A, Fokas E, Wang LF, He H, Kleb B, Niederacher D, Engenhart-Cabillic R, An HX:
Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial
ovarian cancer.
J Cancer Res Clin Oncol. 2011 Apr;137(4):621-7. Epub 2010 Jun 9.
IF: 2.423

Sterzing F, Engenhart-Cabillic R, Flentje M, Debus J:
Image-guided radiotherapy: a new dimension in radiation oncology.
Dtsch Arztebl Int. 2011 Apr;108(16):274-80. Epub 2011 Apr 22.
IF: 2.108

Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R:
Multidisciplinary treatment of brain metastases derived from colorectal cancer
incorporating stereotactic radiosurgery: analysis of 78 patients.
Clin Colorectal Cancer. 2011 Jun;10(2):121-5. Epub 2011 Apr. 22.
IF: 1.735

Strassmann G, Olbert P, Hegele A, Richter D, Fokas E, Timmesfeld N, Hofmann R,
Engenhart-Cabillic R:
Advantage of robotic needle placement on a prostate model in HDR brachytherapy.
Strahlenther Onkol. 2011 Jun;187(6):367-72. Epub 2011 May 17.
IF: 2.541

Gu X, Jelen U, Li J, Jia X, Jiang SB:
A GPU-based finite-size pencil beam algorithm with 3D-density correction for
radiotherapy dose calculation.
Phys Med Biol. 2011 Jun 7;56(11):3337-50.
IF: 3.056

Vorwerk H, Hess CF:
Guidelines for delineation of lymphatic clinical target volumes for high conformal
radiotherapy: head and neck region.
Radiat Oncol. 2011 Aug 19;6(1):97.

Wittig A, Sheu-Grabellus SY, Collette L, Moss R, Brualla L, Sauerwein W:
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples
(results of EORTC trial 11001).
Appl Radiat Isot. 2011 Dec;69(12):1807-12. Epub 2011 Feb 16.
IF: 1.094

Sauerwein W, Moss R, Stecher-Rasmussen F, Rassow J, Wittig A:
Quality management in BNCT at a nuclear research reactor.
Appl Radiat Isot. 2011 Dec;69(12):1786-9.
IF: 1.094

Wittig A, Stecher-Rasmussen F, Hilger RA, Rassow J, Mauri P, Sauerwein W:
Sodium mercaptoundecahydro-closo-dodecaborate (BSH), a boron carrier that merits more attention.
Appl Radiat Isot. 2011 Dec;69(12):1760-4. Epub 2011 Mar 21.
IF: 1.094

2010:

Fokas E, Henzel M, Hamm K, Surber G, Kleiner G, Engenhart-Cabillic R:
Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?
Strahlenther Onkol 2010: 186: 210-217.

Strassmann G, Abdellaoui S, Richter D, Bekkaoui F, Haderlein M, Fokas E, Timmesfeld N,
Vogel B, Henzel M, Engenhart-Cabillic R:
Atlas-based semiautomatic target volume definition (CTV) for head-and-neck tumors.
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1270-6. Epub 2010 Jul 12.

Fokas E, Hänze J, Kamlah F, Eul BG, Lang N, Keil B, Heverhagen JT,
Engenhart-Cabillic R, An H, Rose F:
Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model.
Int J Radiat Oncology Biol Phys 2010, No 5, 1500-1508.

Reich E, Engenhart-Cabillic R, Rosenow F:
Strahlentherapie bei arteriovenösen Malformationen assoziierten Epilepsien.
Zeitschrift für Epileptologie 2. 2010. 238-242.

Fokas E, Kamlah F, Hänze J, Engenhart-Cabillic R, Rose F, An H:
EphA2 blockade enhances the antiendothelial effect of radiation and inhibits irradiated tumor cell-induced migration of endothelial cells.
Thoracic Cancer (2010) 10.1111/j. 1759-7714.2010. 2229x.

He H, Fokas E, You A, Engenhart-Cabillic R, An H:
Siah1 proteins enhance radiosensitivity of human breast cancer cells.
BMC Cancer 10: 403 (03. Aug. 2010).

Fokas E, Henzel M, Engenhart-Cabillic R:
A comparison of Radiotherapy with Radiotherapy plus Surgery for Brain Metastases from Urinary Bladder Cancer. Analysis of 62 Patients.
Strahlentherapie und Onkologie (2010) 186, 565-571.

Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Engenhart-Cabillic R, Fietkau R,
Feyer P, Haase W, Harms W, Rödel C, Soucon R, Wenz F, Sauer R:
Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer.
Strahlentherapie und Onkologie 2010; 186: 651-7.

Kuhn T, Sandner A, Wandt T, Engenhart-Cabillic R, Lammering G, Flentje M,
Grabenbauer G, Schreiber A, Pirnasch A, Dunst J:
Phase 1 trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Annals of Oncology 21: 2284-2289, 2010.

Danova D, Kästner B, Wulff J, Fiebich M, Zink K, Klose K J, Keil B, Heverhagen J.
Reduction Of Uterus Dose In Clinical Thoracic Computed Tomography.
RöFo 182 (2010) 1091-1096

Wulff J, Heverhagen J T, Zink K, Kawrakow I
Investigation of systematic uncertainties in Monte Carlo calculated beam quality factors.
Phys. Med. Biol. 55 (2010) 4481-4493

Wulff J, Zink K
Investigation of correction factors for non-reference conditions in ion chamber photon dosimetry with Monte-Carlo simulations
Z. Med. Phys. 20 (2010) 25-33

Tertel J, Wulff J, Karle H, Zink K
Verification of a commercial implementation of the Macro Monte Carlo electron dose calculation algorithm using the virtual accelerator approach
Z. Med. Phys. 20 (2010) 51-60

2009:

Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P,
Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H:
Phase III comparison of preoperative chemotherapy compared with
chemoradiotherapy in patients with locally advanced adenocarcinoma of the
esophagogastric junction.
J Clin Oncol. 2009 Feb 20;27(6):851-6. Epub 2009 Jan.12.

Kamlah F, Eul BG, Li S, Lang N, Marsh LM, Seeger W, Grimminger F, Rose F, Hänze J:
Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs
survival in a Lewis lung carcinoma cancer model.
Cancer Gene Ther. 2009 Mar;16(3): 195-205. Epub 2008 Sep 26.

Henzel M, Hamm K, Sitter H, Gross MW Surber G, Kleinert G, Engenhart-Cabillic R:
Comparison of stereotactic radiosurgery and fractionated stereotactic radiotherapy of
acoustic nerinomas according to 3-D tumor volume shrinkage and quality of life.
Strahlenther Onkol 2009, No 9, 567-573.

Fokas E, Kraft G, An H, Engenhart-Cabillic R:
Ion beam radiobiology and cancer:Time to update ourselves.
Biochim Biophys Acta 1796 (2009) 216-229.

Xia P, An H, Dang C, Radpour R, Kohler C, Fokas E, Engenhart-Cabillic R, Holzgreve W,
Zhong XY:
Decreased mitochondrial DNA content in blood samples of patients with stage I breast
cancer.
BMC Cancer 2009, 9: 454.

Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R:
Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?
Strahlenther Onkol. 2009 Apr;185(4):235-40. Epub 2009 Apr 16.

Bremke M, Barth PJ, Sesterhenn AM, Budach V, Engenhart-Cabillic R, Werner JA:
Prospective study on neck dissection after primary chemoradiation therapy in stage IV
pharyngeal cancer.
Anticancer Res. 2009 Jul;29(7):2645-54.

Teymoortash A, Müller F, Juricko J, Bieker M, Mandic R, Librizzi D, Höffken H,
Pfestroff A, Werner JA:
Botulinum toxin prevents radiotherapy-induced salivary gland damage.
Oral Oncol. 2009 Aug;45(8):737-9. Epub 2009 Feb 11.

Scherf C, Peter C, Moog J, Licher J, Kara E, Zink K, Rödel C, Ramm U
Silicon diodes as an alternative to diamond detectors for depth dose curves and profile measurements of photon and electron radiation
Strahlenther Onkol 185 (2009) 530-536

Wulff J, Ubrich F, Zink K
Comment on "Monte Carlo simulation of an x-ray volume imaging cone beam CT unit"
Med. Phys. 36 (2009) 127-136

Zink K, Wulff J
Positioning of a plane-parallel ionization chamber in clinical electron beams and the impact on perturbation factors
Phys. Med. Biol. 54 (2009) 2421-2435

2008:

Hamm K, Henzel M, Gross MW, Surber G, Kleinert G, Engenhart-Cabillic R:
Radiosurgery/Stereotactic Radiotherapy in the therapeutical concept for skull base
meningiomas.
Zentralbl Neurochir 2008 Feb;69(1):14-21

Henzel M, Hamm K, Gross MW Surber G, Kleinert G, Failing T, Sitter H, Strassmann G,
Engenhart-Cabillic R:
Fractionated stereotactic radiotherapy of glomus jugulare tumors.
Strahlenther Onkol 2007; 183: 557-562.

Wang L-F, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A,
Engenhart-Cabillic R, An H:
Increased expression of EphA2 correlates with adverse outcome in primary and
recurrent glioblastoma multiforme patients.
Oncol Rep. 2008 Jan;19(1):151-6

Eich HT, Engenhart-Cabillic R, Hansemann K, Lukas P, Schneeweiss A,
Seegenschmiedt H, Skripnitchenko R, Staar S, Willich N, Müller RP:
Quality control of involves filed radiotherapy in patients with early-favorable (HD10)
and early-unfavorable (HD11) Hodgkin’s lymphoma – An analysis of the German
Hodgkin Study Group (GHSG)
Int J Radiat Oncol Biol Phys 2008 Aug 1,71(5):1419-24.

Eich HT; Müller RP, Engenhart-Cabillic R, Lukas P, Schmidberger H, Staar S, Willich N:
German Hodgkin Study Group. Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).
Strahlenther Onkol. 2008 Aug; 184(8):406-10.

Sure U, Sürücu O, Engenhart-Cabillic R:
Embolization before radiosurgery reduces the obliteration rate of arteriovenous
malformations.
Neurosurgery 2008 Aug; 63(2): E376, author reply E376.

Hamm KD, Gross MW, Fahrig A, Surber G, Henzel M, Kleinert G, Grabenbauer G,
Engenhart-Cabillic R:
Stereotactic radiotherapy for the treatment of nonacoustic schwannomas.
Neurosurgery. 2008 May;62(5 Suppl):A29-36; discussion A36.

Hamm KD, Henzel M, Gross MW, Surber G, Kleinert G, Engenhart-Cabillic R:
Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base
meningiomas.
Zentralbl Neurochir. 2008 Feb; 69(1):14-21.

Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, Engenhart-Cabillic R,
An HX:
Increased expression of EphA7 correlates with adverse outcome in primary and
recurrent glioblastoma multiforme patients.
BMC Cancer. 2008 Mar 25;8:79.